US Food & Drug Administration (FDA) Commissioner Scott Gottlieb outlined new steps and actions to advance FDA’s consideration of a framework for the lawful marketing of appropriate cannabis and cannabis-derived products under existing authorities. In a statement, Gottlieb said, “In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and its components, including cannabidiol (CBD)....